| Literature DB >> 31600730 |
Yuri Tanaka1, Taisuke Uchida1, Hideki Yamaguchi1, Yohei Kudo1, Tadato Yonekawa1, Masamitsu Nakazato1.
Abstract
SUMMARY: We report the case of a 48-year-old man with thyroid storm associated with fulminant hepatitis and elevated levels of soluble interleukin-2 receptor (sIL-2R). Fatigue, low-grade fever, shortness of breath, and weight loss developed over several months. The patient was admitted to the hospital because of tachycardia-induced heart failure and liver dysfunction. Graves' disease with heart failure was diagnosed. He was treated with methimazole, inorganic iodide, and a β-blocker. On the day after admission, he became unconscious with a high fever and was transferred to the intensive care unit. Cardiogenic shock with atrial flutter was treated with intra-aortic balloon pumping and cardioversion. Hyperthyroidism decreased over 10 days, but hepatic failure developed. He was diagnosed with thyroid storm accompanied by fulminant hepatitis. Laboratory investigations revealed elevated levels of sIL-2R (9770 U/mL). The fulminant hepatitis was refractory to plasma exchange and plasma filtration with dialysis, and no donors for liver transplantation were available. He died of hemoperitoneum and gastrointestinal hemorrhage due to fulminant hepatitis 62 days after admission. Elevated circulating levels of sIL-2R might be a marker of poor prognosis in thyroid storm with fulminant hepatitis. LEARNING POINTS: The prognosis of thyroid storm when fulminant hepatitis occurs is poor. Liver transplantation is the preferred treatment for fulminant hepatitis induced by thyroid storm refractory to plasma exchange. Elevated levels of soluble interleukin-2 receptor might be a marker of poor prognosis in patients with thyroid storm.Entities:
Keywords: 2019; Adult; Alanine aminotransferase; Albumin; Alkaline phosphatase; Ammonia; Asian - Japanese; Aspartate transaminase; Atrial fibrillation; Beta-blockers; Bilirubin; Brain natriuretic peptide; Breathing difficulties; C-reactive protein; CT scan; Calcium (serum); Cardiogenic shock; Cardiology; Cardiomegaly; Coagulopathy; Creatinine; Dialysis; Dyspnoea; Echocardiogram; FT3; FT4; Fatigue; Fulminant hepatitis*; Gastroenterology; Glucocorticoids; Glucose; Glucose (blood); Goitre; Graves' disease; Heart; Heart failure; Hydrocortisone; Hyperammonemia*; Hyperhidrosis; Hyperthyroidism; Hypoglycaemia; Hypoxia; Intra-aortic balloon pumping*; Japan; Jaundice; Lactate dehydrogenase; Landiolol hydrochloride*; Liver; Liver dysfunction*; Liver failure; Male; Metabolic acidosis; Methimazole; Oedema; Plasma exchange; Potassium; Potassium iodide; Propylthiouracil; Prothrombin time; Pyrexia; Renal failure; September; Soluble IL-2 receptor*; TSH; Tachycardia; Thyroid; Thyroid antibodies; Thyroid storm; Thyroxine (T4); Transaminase; Triiodothyronine (T3); Unique/unexpected symptoms or presentations of a disease; Weight loss; X-ray
Year: 2019 PMID: 31600730 PMCID: PMC6765318 DOI: 10.1530/EDM-19-0078
Source DB: PubMed Journal: Endocrinol Diabetes Metab Case Rep ISSN: 2052-0573
Summary of laboratory testing results.
| Laboratory test | Values | Reference range |
|---|---|---|
| Peripheral blood | ||
| Leukoses (x 103/μ | 11.1 | 3.3–8.6 |
| Erythrocytes (x 104/μL) | 434 | 435–555 |
| Hemoglobin (g/dL) | 13.1 | 13.7–16.8 |
| Platelets (x 104/μL) | 28.9 | 15.8–34.8 |
| Serum | ||
| Albumin (g/dL) | 2.56 | 4.1–5.1 |
| Total bilirubin (mg/dL) | 2.5 | 0.4–1.5 |
| Direct bilirubin (mg/dL) | 1.2 | 0.1–0.3 |
| Aspartate transaminase (U/L) | 1458 | 13–30 |
| Alanine aminotransferase (U/L) | 555 | 10–42 |
| Lactate dehydrogenase (U/L) | 3266 | 124–222 |
| Alkaline phosphatase (U/L) | 370 | 103–322 |
| Glucose (mg/dL) | 35 | 73–109 |
| Blood urea nitrogen (mg/dL) | 42.3 | 8–20 |
| Creatinine (mg/dL) | 2.16 | 0.7–1.1 |
| Na (mmol/L) | 141 | 138–145 |
| K (mmol/L) | 5.4 | 3.6–4.8 |
| Ca (mg/dL) | 7.6 | 8.8–10.1 |
| CRP (mg/dL) | 1.81 | <0.14 |
| PT (%) | 19.1 | 80–100 |
| Ammonia (μg/dL) | 203 | 12–66 |
| BNP (pg/mL) | 397.3 | <18.4 |
| Free T3 (pg/mL) | 7.5 | 1.9–3.2 |
| Free T4 (ng/dL) | 6.0 | 0.7–1.5 |
| TSH (μIU/mL) | <0.01 | 0.4–5.0 |
| TRAb (%) | 40 | <15% |
| TSAb (%) | 645 | <120% |
| Anti-TgAb (IU/mL) | 40.0 | 141 10 6 |
| Anti-TPOAb (IU/mL) | 29.9 | 1.1–5.2 |
| ANA | (–) | |
| AMA (units) | <1.5 | <20 |
| HBs Ag | (–) | |
| HCV Ab | (–) | |
| SIL-2R (U/mL) | 9770 | 145–519 |
AMA, anti-mitochondrial antibody; ANA, antinuclear antibody; Anti-TgAb., anti-thyroglobulin antibody; Anti-TPOAb, anti-thyroid peroxidase antibody; BNP, brain natriuretic peptide; CRP, C-reactive protein; HBs Ag, hepatitis B surface antigen; HCV Ab, anti-hepatitis C virus antibody; PT, prothrombin time; sIL-2R_ soluble interleukin-2 receptor; T3, triiodothyronine; T4, thyroxine; TRAb, thyroid-stimulating homione receptor antibody; TSAb, thyroid-stimulating antibody.
Figure 1(A) Chest x-ray showed cardiomegaly and a pleural effusion. (B) Cervical computed tomography (CT) showed a swollen thyroid. (C) Abdominal CT showed ascites without any organic lesions in the liver.
Figure 2Clinical course.